TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31385636

Group type: EXPERIMENTAL
Intervention: A‐AOMI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: S‐AOMI
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AO
Number of subjects: 50
Study: 28823491

Group type: EXPERIMENTAL
Intervention: Weekly two‐hour small group sessions led by an occupational therapist for six weeks focusing on nutrition, physical activity, and self‐management strategies
Number of subjects: 0
Study: 25243910

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secukinumab (300 mg and 150 mg)
Number of subjects: 0
Study: 23022106

Group type: EXPERIMENTAL
Intervention: 10‐MDP‐containing luting system (Clearfil Ceramic Primer plus Panavia F 2.0)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self‐adhesive cement (Bifix SE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Airborne particle abrasion with 25‐μm Al(2)O(3) particles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Airborne particle abrasion with 50‐μm Al(2)O(3) particles
Number of subjects: 40

Group type: COMPARATOR
Intervention: Airborne particle abrasion with 110‐μm Al(2)O(3) particles
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment (Group 1 - NT)
Number of subjects: 40
Study: 20380784

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (CACR)
Number of subjects: 16
Study: 19826172

Group type: EXPERIMENTAL
Intervention: Supervised exercise comprising high intensity cardiovascular and resistance training, relaxation and body awareness training, massage, nine hours weekly for six weeks in addition to conventional care
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 269

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 269
Study: 18051004

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide gel with potassium nitrate and fluoride (Opalescence 15% PF, OP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide with amorphous calcium phosphate (Nite White 16%, NW)
Number of subjects: 32
Study: 15510462

Group type: EXPERIMENTAL
Intervention: Myoconjunctival technique
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine technique
Number of subjects: 30
Study: 11335905

Group type: EXPERIMENTAL
Intervention: Interstitial photodynamic therapy with rotating and reciprocating optical fibers
Number of subjects: 3
Study: 9440013

Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercise (PME) with biofeedback, performed three times per week for 12 weeks.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no PME instruction).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pelvic muscle exercise (PME) with biofeedback.
Number of subjects: 53
Study: 7890023

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.0125 mg per kg body weight)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Scopolamine (0.5 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study: 2904824

Group type: EXPERIMENTAL
Intervention: Astemizole 30 mg taken orally once daily for 1 week
Number of subjects: 0
Study: 31854098

Group type: EXPERIMENTAL
Intervention: 24-LIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 24-HIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 26-LIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 26-HIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 28-LIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 28-HIP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 0
Study: 30408456

Group type: EXPERIMENTAL
Intervention: Immediate postpartum insertion of levonorgestrel contraceptive implants
Number of subjects: 183

Group type: COMPARATOR
Intervention: Delayed insertion of levonorgestrel contraceptive implants
Number of subjects: 183
Study: 28780299

Group type: EXPERIMENTAL
Intervention: Protective lead curtains (LC)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nonprotective lead curtain (n-LC)
Number of subjects: 123
Study: 25793928

Group type: EXPERIMENTAL
Intervention: Low-dose RAI (1110 MBq)
Number of subjects: 102

Group type: COMPARATOR
Intervention: High-dose RAI (3700 MBq)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 24011332

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 679

Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stent (R-ZES)
Number of subjects: 679
Study: 21138610

Group type: EXPERIMENTAL
Intervention: Magazine with food advertisements
Number of subjects: 47

Group type: COMPARATOR
Intervention: Magazine with no food advertisements
Number of subjects: 47
Study: 18551327

Group type: EXPERIMENTAL
Intervention: C-Flex
Number of subjects: 184

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 184
Study: 17760282

Group type: EXPERIMENTAL
Intervention: Tactile cueing using a vibrating electromechanical tactile vest activated in clockwise or counterclockwise direction during yaw rotation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tactile cueing using a vibrating electromechanical tactile vest
Number of subjects: 15
Study: 16266962

Group type: EXPERIMENTAL
Intervention: Budesonide via Clickhaler (n=110)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Budesonide via Turbuhaler (n=112)
Number of subjects: 222
Study: 11990435

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Open flap debridement (Control)
Number of subjects: 10
Study: 10453668

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors of autologous origin, obtained by plasmapheresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No membrane or barrier technique
Number of subjects: 0
Study: 8830061

Group type: EXPERIMENTAL
Intervention: Nefazodone, 200 mg twice daily + Triazolam, 0.25 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Alprazolam, 1 mg twice daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Alprazolam, 1 mg twice daily + Nefazodone, 200 mg
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Lorazepam, 2 mg twice daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 2138496

Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7466726

Group type: EXPERIMENTAL
Intervention: BCG immunostimulation by scarifications (BCG-A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intrapleural BCG treatment followed by scarifications (BCG-B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BCG-A
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: BCG-B
Number of subjects: 54
Study: 30325870

Group type: EXPERIMENTAL
Intervention: Robot-assisted radical prostatectomy (RARP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open radical prostatectomy (ORP)
Number of subjects: 0
Study: 28586918

Group type: EXPERIMENTAL
Intervention: Nebulized Hypertonic Saline (HS) 3% - 4 mL, two 20-minute treatments
Number of subjects: 777

Group type: COMPARATOR
Intervention: Normal Saline (NS) 0.9% - 4 mL, two 20-minute treatments
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Nebulized Hypertonic Saline (HS) 3%
Number of subjects: 777

Group type: COMPARATOR
Intervention: Normal Saline (NS) 0.9%
Number of subjects: 777
Study: 25865431

Group type: EXPERIMENTAL
Intervention: Recovery Coaches in addition to traditional child welfare services
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Traditional child welfare services
Number of subjects: 2160
Study: 23771830

Group type: EXPERIMENTAL
Intervention: EXP condition (cognitive activity test)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON condition (passive neutral observation task)
Number of subjects: 12
Study: 21736837

Group type: EXPERIMENTAL
Intervention: Olive oil enriched with 45 μg MK-7
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Olive oil enriched with 90 μg MK-7
Number of subjects: 12

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 12
Study: 19371887

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg daily with breakfast for 12 weeks
Number of subjects: 923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Silodosin
Number of subjects: 923
Study: 16766337

Group type: EXPERIMENTAL
Intervention: Standard oral itraconazole pulse therapy for 3 months (200 mg x 2/day for 1 week/month) followed by an additional single course (200 mg/day for 7 days) after 3 months.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Modified itraconazole pulse therapy (6-week interval) x3 followed by an additional single course (200 mg x 2/day for 7 days) after 3 months.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Both regimens (A and B) combined results.
Number of subjects: 104
Study: 15232117

Group type: EXPERIMENTAL
Intervention: Presence of PFO in patients younger than 55 years
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Presence of PFO in patients aged 55 to 64 years
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Presence of PFO in patients aged 65 years or older
Number of subjects: 250
Study: 11738071

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (100 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study: 9226393

Group type: EXPERIMENTAL
Intervention: bioabsorbable polyglycolic‐polylactic membrane (PGA/PLA group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: non‐resorbable expanded polytetrafluoroethylene membrane (ePTFE group)
Number of subjects: 30
Study: 7904400

Group type: EXPERIMENTAL
Intervention: Acrivastine (8 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 20
Study: 3304003

Group type: COMPARATOR
Intervention: Midazolam 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 0
Study: 31146610

Group type: EXPERIMENTAL
Intervention: Locked-continuous closure technique
Number of subjects: 86

Group type: COMPARATOR
Intervention: Unlocked-continuous closure technique
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 86
Study: 29097820

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of suprahyoid muscles
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard orofacial rehabilitation without electrical stimulation (Control)
Number of subjects: 54
Study: 26905469

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroid administration before elective caesarean section at term
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24753279

Group type: EXPERIMENTAL
Intervention: Unplugged program (12 one-hour interactive sessions delivered by teachers)
Number of subjects: 7079
Study: 24227357

Group type: EXPERIMENTAL
Intervention: Intraoperative superficial cervical plexus block (SCPB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Incisional local anaesthesia (control)
Number of subjects: 58
Study: 21219436

Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus insulin injection
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion
Number of subjects: 10
Study: 18793867

Group type: EXPERIMENTAL
Intervention: flat posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: long lordosis posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: short lordosis posture
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: slumped posture
Number of subjects: 10
Study: 16835281

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg/month)
Number of subjects: 116
Study: 12830733

Group type: EXPERIMENTAL
Intervention: Novel targeted therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonspecific cytotoxic chemotherapeutic agents
Number of subjects: 0
Study: 10951687

Group type: EXPERIMENTAL
Intervention: Project NetWork case management services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no Project NetWork services)
Number of subjects: 0
Study: 9124056

Group type: EXPERIMENTAL
Intervention: Oral salbutamol (0.1 mg/kg per dose, four times a day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MDI salbutamol (200 micrograms per dose, every 3 h)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no bronchodilator therapy)
Number of subjects: 31
Study: 7908144

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray (BDP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo/azelastine treatment
Number of subjects: 130
Study: 3223752

Group type: EXPERIMENTAL
Intervention: Pivmecillinam (perioperative treatment from the evening before the operation to the day after removal of the catheter)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no perioperative treatment)
Number of subjects: 52
Study: 28766183

Group type: EXPERIMENTAL
Intervention: Guided imagery intervention for 35 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 48
Study: 25308771

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride 50 mg/day for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 25910064

Group type: EXPERIMENTAL
Intervention: Low-volume preparation (15 mg bisacodyl plus 2 L polyethylene glycol [PEG] solution)
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-volume preparation (4 L PEG)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-volume preparation
Number of subjects: 120

Group type: COMPARATOR
Intervention: High-volume preparation
Number of subjects: 120
Study: 22944093

Group type: EXPERIMENTAL
Intervention: ThoraCAB
Number of subjects: 184

Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 184
Study: 20923486

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 5238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study: 17956585

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 16484712

Group type: COMPARATOR
Intervention: Canine scent detection for lung cancer
Number of subjects: 169

Group type: COMPARATOR
Intervention: Canine scent detection for breast cancer
Number of subjects: 169
Study: 12881209

Group type: EXPERIMENTAL
Intervention: Oral vitamin C (1,000 mg) and vitamin E (800 IU) daily for 6 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Matching placebo for 6 months
Number of subjects: 49
Study: 10564633

Group type: EXPERIMENTAL
Intervention: 1% or fat-free milk (low-fat milk)
Number of subjects: 35000

Group type: COMPARATOR
Intervention: High-fat milk (control)
Number of subjects: 35000
Study: 8938467

Group type: EXPERIMENTAL
Intervention: Continuous epidural bupivacaine (0.25%) throughout labor
Number of subjects: 70

Group type: COMPARATOR
Intervention: Epidural bupivacaine until 8-cm dilatation of the cervix
Number of subjects: 70
Study: 1914560

Group type: EXPERIMENTAL
Intervention: Fluid gain less than 1 L by 36 hours
Number of subjects: 89

Group type: COMPARATOR
Intervention: Fluid gain greater than 1 L by 36 hours
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Independent predictor of survival based on fluid balance
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Decrease in EVLW by more than 15 percent
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Median duration of days on the ventilator, ICU days, and days of hospitalization for less than 1 L fluid gain
Number of subjects: 89
Study: 6114721

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (Darvon‐N)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methadone hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up interviews at one and six months after treatment
Number of subjects: 0
Study: 30501950

Group type: EXPERIMENTAL
Intervention: Aspirin + Ticagrelor 90 mg twice per day
Number of subjects: 140

Group type: COMPARATOR
Intervention: Aspirin + Clopidogrel 75 mg once per day
Number of subjects: 140
Study: 29281628

Group type: EXPERIMENTAL
Intervention: e-STI testing and results service
Number of subjects: 2072

Group type: COMPARATOR
Intervention: Control group (bespoke website of local sexual health clinics)
Number of subjects: 2072
Study: 25857722

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 37

Group type: COMPARATOR
Intervention: Baseline Galectin-3 levels in LRA
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Baseline Galectin-3 levels in both RA subsets (ERA and LRA)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Circadian variation of Galectin-3
Number of subjects: 37
Study: 23399479

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 21145828

Group type: EXPERIMENTAL
Intervention: High-dose ursodesoxycholic acid (HD-UDCA) 28-35 mg/kg per day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: High-dose ursodesoxycholic acid (HD-UDCA)
Number of subjects: 126
Study: 19246357

Group type: EXPERIMENTAL
Intervention: Diet with 15% protein
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Diet with 25% protein
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Diet with 20% fat
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Diet with 40% fat
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Diet with 65% carbohydrates
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Diet with 35% carbohydrates
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: All diets
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Attendance at group sessions
Number of subjects: 811
Study: 17847941

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) - TSE
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) - HASTE
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance (MR) - True FISP
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Age correlation
Number of subjects: 76
Study: 15088420

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, oral single dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg, oral single dose)
Number of subjects: 30
Study: 11326215

Group type: EXPERIMENTAL
Intervention: Glider swing intervention (20 minutes each day for 10 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (5-day baseline phase and 5-day posttreatment phase)
Number of subjects: 30
Study: 9058651

Group type: EXPERIMENTAL
Intervention: Dynamic muscle training
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Muscle relaxation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study: 8201382

Group type: EXPERIMENTAL
Intervention: 131I‐mAbF19 administered intravenously
Number of subjects: 17
Study: 3229484

Group type: EXPERIMENTAL
Intervention: Dry air (DA) nasal breathing for 30 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Room air (RA) nasal breathing
Number of subjects: 11
Study: 28899715

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) supplementation (100,000 loading dose followed by 4000 IU daily for 16 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D) supplementation
Number of subjects: 120
Study: 28577679

Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 8399

Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 8399
Study: 26643822

Group type: EXPERIMENTAL
Intervention: Individually tailored interdisciplinary interventions based on the use of 3-dimensional instrumented gait analysis (IGA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individually tailored interdisciplinary interventions based on the use of IGA
Number of subjects: 0
Study: 23146065

Group type: EXPERIMENTAL
Intervention: Topical acetyl hexapeptide-8 (AH8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22027547

Group type: EXPERIMENTAL
Intervention: 2-cm resection margin
Number of subjects: 936

Group type: COMPARATOR
Intervention: 4-cm resection margin
Number of subjects: 936
Study: 17686479

Group type: EXPERIMENTAL
Intervention: Anastrozole or Letrozole
Number of subjects: 0
Study: 17063127

Group type: EXPERIMENTAL
Intervention: Internet-based Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 958

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 958
Study: 12635780

Group type: EXPERIMENTAL
Intervention: Palatal plate therapy (PPG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 20
Study: 10644314

Group type: EXPERIMENTAL
Intervention: Fat meal (60% calories from fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Carbohydrate meal (60% calories from carbohydrate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control period (preprandial)
Number of subjects: 18
Study: 9182113

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (bd)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Cefaclor (tds)
Number of subjects: 167
Study: 1825278

Group type: EXPERIMENTAL
Intervention: Effective nursing intervention, antifungal medication, and a moisture barrier ointment
Number of subjects: 0
Study: 6210180

Group type: EXPERIMENTAL
Intervention: 100 mg dimetophrine tablets
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2.5 mg midodrine tablets
Number of subjects: 30
Study: 30880286

Group type: EXPERIMENTAL
Intervention: Polysomnographic titration (PSG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (daytime titration followed by sham PSG)
Number of subjects: 60
Study: 28712371

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32